Featured Research

from universities, journals, and other organizations

Gene Therapy: Oral Gene Delivery System For Inflammatory Bowel Disease Works, Study Shows

Date:
May 22, 2008
Source:
Northeastern University
Summary:
Inflammatory bowel disease (IBD) afflicts as many as 10 out of 100,000 people in the United States and currently available treatment options are short-term and invasive with toxic side effects. Now medical scientists are successfully developing a safe and effective, orally administered non-viral gene delivery system that promises a painless treatment option with long-term effects and aims to ultimately replace the frequent injection regimen offered to patients today.

Inflammatory bowel disease (IBD) afflicts as many as 10 out of 100,000 people in the United States and currently available treatment options are short-term and invasive with toxic side effects. Northeastern University professor Mansoor Amiji and his team are successfully developing a safe and effective, orally administered non-viral gene delivery system that promises a painless treatment option with long-term effects and aims to ultimately replace the frequent injection regimen offered to patients today.

The most recent findings of the four-year project evaluating the efficiency of Nanoparticles-in-Microsphere Oral Systems (NiMOS) oral gene delivery system have just been published.

The article discusses the effectiveness of oral interleukin-10 or IL-10 (anti-inflammatory protein molecules) gene therapy for the treatment of IBD. The findings indicate that upon oral administration of NiMOS, transfection and local expression of IL-10 can not only suppress the levels of pro-inflammatory cytokines, but can also increase body weight, restore colon length and weight, and suppress inflammatory tissue response.

“Our findings provide highly encouraging evidence of oral gene delivery for efficient transfection,” Amiji, Professor and Associate Chairman of the Pharmaceutical Sciences Department in Northeastern’s Bouvé College of Health Sciences. “The reality of being able to produce drugs at the site of inflammation promises to eliminate frequent invasive administration of drugs with strong side effects.”

The researchers compared the capacity and efficiency of IL-10-expressing plasmid DNA administered in NiMOS with those encapsulated in gelatin nanoparticles in colitis-induced mice. Over the course of eight days of oral gene therapy treatment, the animals receiving NiMOS treatment showed body weight gain back to the original four days after the loss of more than 10% of the original weight. Amiji and his co-author, Dr. Mayank Bhavsar (a recent graduate from Amiji’s lab) also observed the restoration of colon length and weight in this group of mice, as well as significant decrease in disease activity.

“These results can only be attributed to the increased local levels of IL-10 upon treatment,” added Amiji, who is also the Co-Director of Nanomedicine Education and Research Consortium (NERC) at Northeastern University. “This is evidence that NiMOS treatment is highly effective, therefore promising a clinically translatable option for IBD treatment that offers a very high patient-compliant therapeutic approach.”

Although preclinical studies have been done successfully on delivery of plasmid DNA encoding for IL-10 using viral vectors, the potential toxicity of viruses, especially upon chronic administration poses significant concern.

“Being a non-viral delivery system makes NiMOS a revolutionary form of oral gene therapy,” said Amiji. “Non-viral delivery that provides efficient transfection has the potential for research to be translated into clinical reality, especially for the treatment of chronic diseases such as IBD.”

The findings discussed in this paper are part of an ongoing, four-year research project funded by a $1.34 million grant by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH). The research team also includes as co-investigator, Dr. Akio Ohta, Assistant Professor of Pharmaceutical Sciences at Northeastern and a member of the New England Inflammation and Tissue Protection Institute, and as consultant, Dr. Takeshi Sano, Associate Professor of Radiology and Director of the Center for Molecular Imaging, Diagnosis, and Therapy at Beth Israel Deaconess Medical Center and Harvard Medical School.


Story Source:

The above story is based on materials provided by Northeastern University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Oral IL-10 Gene Delivery in a Microsphere-based Formulation for Local Transfection and Therapeutic Efficacy in Inflammatory Bowel Disease. Gene Therapy, May, 2008. doi:10.1038/gt.2008.67

Cite This Page:

Northeastern University. "Gene Therapy: Oral Gene Delivery System For Inflammatory Bowel Disease Works, Study Shows." ScienceDaily. ScienceDaily, 22 May 2008. <www.sciencedaily.com/releases/2008/05/080520163044.htm>.
Northeastern University. (2008, May 22). Gene Therapy: Oral Gene Delivery System For Inflammatory Bowel Disease Works, Study Shows. ScienceDaily. Retrieved August 23, 2014 from www.sciencedaily.com/releases/2008/05/080520163044.htm
Northeastern University. "Gene Therapy: Oral Gene Delivery System For Inflammatory Bowel Disease Works, Study Shows." ScienceDaily. www.sciencedaily.com/releases/2008/05/080520163044.htm (accessed August 23, 2014).

Share This




More Health & Medicine News

Saturday, August 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) — An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) — Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) — Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) — It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins